|
|
|
European Pharmaceutical Contractor
|
Site Selection and Investigator Identification
Highly critical to the success of any study, these two issues require the utmost care. The decision-making process regarding both site and investigator should make full use of all local expertise:
Local opinion leaders will be well acquainted with the available professionals in the
area, as well as with its hospital structure and facilities
Local CROs and pharmaceutical companies' affiliate offices (affiliates) will have
hands-on experience of potential investigators and sites
This expertise should provide valuable information regarding site potential and suitability for trial requirements, for example available beds, medical/lab equipment, clinical supply, storage facilities and so on. They can also be helpful for assessing a site's desirability, for instance location, physical layout, access to IRB/IEC, quality of clinical trial teams and a suitable patient pool. Utilising these resources, whilst fundamental, is not without potential problems.
For example one should always be aware of the risk of commercial interests affecting advice given by affiliates during site/investigator selection. In an emerging scientific market commercial potential is limited, and therefore sales and marketing opportunities should be carefully balanced with clinical development. In our opinion, the emphasis should be put on clinical development performance. It is much more important to assess a site's real suitability and an investigator's capabilities in new drug trial implementation, rather than future marketing potential.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
In our Summer 2002 issue, Dr Milen Vrabevski, Medical Director at Comac Medical, began an in-depth overview of clinical trials in his native Bulgaria. Here he continues his investigation of the advantages and potential pitfalls for multinational pharmaceuticals operating in emerging scientific markets.
Dr Milen Vrabevski is Medical Director of Comac Medical Ltd., a full service small CRO based in Sofia, Bulgaria. He has over five years of experience in the pharmaceutical industry, mainly in the field of clinical research.
After graduating from the Medical University of Varna in 1995, Milen began his career working as a Junior Doctor in a surgery department, and then as a Medical Representative of a pharmaceutical company before founding Comac Medical Ltd. in 1997, assuming the position of Director.
Being one of the pioneers in the GCP and Quality of Life (QoL) area in his country, Milen has participated in conducting all company clinical studies and QoL projects.
|
|
|
|
|
|
 |
Industry Events |
 |
10th-Anniversary Event RFID Journal LIVE! 2012
3-5 April 2012, Walt Disney World Swan and Dolphin Resort, Orlando, Florida
RFID Journal LIVE! 2012, our tenth annual conference and exhibition, is the only event where you can learn how to use RFID technologies to improve your pharmaceutical and medical packaging business, from real-world case studies across all applications, including asset tracking, logistics and transportation, supply chain management, warehouse and inventory management, security and more. Learn from a customized program featuring more than 50 end-user case studies and 8 industry-specific and how-to conference tracks.
More info >> |
|
 |
News and Press Releases |
 |
Firstan Ltd are first to achieve the new Pharmaceutical PS9000:2011 quality standard
Firstan Ltd, the UK’s leading independently owned Pharmaceutical and Food Carton producer have become the first UK Packaging company to achieve the new Pharmaceutical PS9000:2011 quality standard for its Healthcare Division. This standard was published in September 2011 in consultation with industry suppliers, pharmaceutical companies and other stakeholder organisations. Firstan have held the Pharmaceutical accreditation for almost 20 years.
More info >> |
|
|
